CCL17 and interstitial lung disease: As shown in Figure 4, there were no significant differences in serum TARC levels between SSc patients who newly developed SSc-ILD during the follow-up period and those who did not (408.7 ± 154.6 pg/mL vs. 388.0 ± 236.7 pg/mL, p = 0.538).